top of page
News
October 2024
Synendos Secures Innosuisse Funding to Advance Clinical Development of SYT-510
January 2024
Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510
July 2023
Synendos Therapeutics AG announces that co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, presented groundbreaking new findings on an endocannabinoid transporter at the 10th Gordon Research Conference
March 2023
Synendos featured in Scrip article
October 2022
Synendos Therapeutics has been awarded with the Innosuisse Certificate
bottom of page